148 related articles for article (PubMed ID: 31036830)
1. Downregulation of CYB5D2 is associated with breast cancer progression.
Ojo D; Rodriguez D; Wei F; Bane A; Tang D
Sci Rep; 2019 Apr; 9(1):6624. PubMed ID: 31036830
[TBL] [Abstract][Full Text] [Related]
2. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
3. CYB5D2 displays tumor suppression activities towards cervical cancer.
Xie Y; Shen YT; Kapoor A; Ojo D; Wei F; De Melo J; Lin X; Wong N; Yan J; Tao L; Major P; Tang D
Biochim Biophys Acta; 2016 Apr; 1862(4):556-565. PubMed ID: 26692170
[TBL] [Abstract][Full Text] [Related]
4. CYB5D2 enhances HeLa cells survival of etoposide-induced cytotoxicity.
Xie Y; Bruce A; He L; Wei F; Tao L; Tang D
Biochem Cell Biol; 2011 Jun; 89(3):341-50. PubMed ID: 21639828
[TBL] [Abstract][Full Text] [Related]
5. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
Ojo D; Wu Y; Bane A; Tang D
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
[TBL] [Abstract][Full Text] [Related]
6. Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer.
Ojo D; Seliman M; Tang D
BBA Clin; 2017 Dec; 8():56-65. PubMed ID: 28879097
[TBL] [Abstract][Full Text] [Related]
7. EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer.
Katsyv I; Wang M; Song WM; Zhou X; Zhao Y; Park S; Zhu J; Zhang B; Irie HY
Oncotarget; 2016 Oct; 7(43):69592-69605. PubMed ID: 27612429
[TBL] [Abstract][Full Text] [Related]
8. CYB5D2 requires heme-binding to regulate HeLa cell growth and confer survival from chemotherapeutic agents.
Bruce A; Rybak AP
PLoS One; 2014; 9(1):e86435. PubMed ID: 24466094
[TBL] [Abstract][Full Text] [Related]
9. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
10. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
11. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
12. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
[TBL] [Abstract][Full Text] [Related]
13. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
14. ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
Amin R; Morita-Fujimura Y; Tawarayama H; Semba K; Chiba N; Fukumoto M; Ikawa S
Mol Oncol; 2016 Apr; 10(4):575-93. PubMed ID: 26704768
[TBL] [Abstract][Full Text] [Related]
15. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
[TBL] [Abstract][Full Text] [Related]
16. Placental Kisspeptins Differentially Modulate Vital Parameters of Estrogen Receptor-Positive and -Negative Breast Cancer Cells.
Rasoulzadeh Z; Ghods R; Kazemi T; Mirzadegan E; Ghaffari-Tabrizi-Wizsy N; Rezania S; Kazemnejad S; Arefi S; Ghasemi J; Vafaei S; Mahmoudi AR; Zarnani AH
PLoS One; 2016; 11(4):e0153684. PubMed ID: 27101408
[TBL] [Abstract][Full Text] [Related]
17. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
Chung YL; Sheu ML; Yang SC; Lin CH; Yen SH
Int J Cancer; 2002 Jan; 97(3):306-12. PubMed ID: 11774281
[TBL] [Abstract][Full Text] [Related]
18. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
19. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
[TBL] [Abstract][Full Text] [Related]
20. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer.
Zhao XG; Hu JY; Tang J; Yi W; Zhang MY; Deng R; Mai SJ; Weng NQ; Wang RQ; Liu J; Zhang HZ; He JH; Wang HY
Cell Death Dis; 2019 Jun; 10(7):479. PubMed ID: 31209222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
